Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years

Carla E. M. Hollak, Nadia Belmatoug, J. Alexander Cole, Stephan vom Dahl, Patrick B. Deegan, Jack Goldblatt, Barry Rosenbloom, Laura van Dussen, Anna Tylki-Szymańska, Neal J. Weinreb, Ari Zimran, Maria Domenica Cappellini

Research output: Contribution to journalArticle*Academicpeer-review


The characteristics of Gaucher disease (GD) associated with persistent thrombocytopenia despite imiglucerase enzyme therapy in type 1 GD (GD1) were investigated by retrospective analysis of International Collaborative Gaucher Group (ICGG) Registry data. The study involved 1016 GD1 patients with an intact spleen for whom date of diagnosis, therapy initiation, and platelet counts were known, and who received continuous imiglucerase therapy for 4 to 5 years. These patients were stratified by last platelet count: >= 120 x 10(9)/l (n = 772); >= 100 to <120 x 10(9)/l (n = 94); =80 to <100 x 10(9)/l (n = 80); and <80 x 10(9)/l (n = 70; 20 with <60 x 109/l) and characterized by initial and cumulative average imiglucerase dose, body mass index, platelet count, anaemia, hepatomegaly, splenomegaly, and skeletal assessments at baseline and after 45 years of therapy. Statistically significant associations were found between persistent thrombocytopenia and baseline platelet count ( <80 x 10(9)/l), splenomegaly, and anaemia (all P <0.0001). After 45 years, statistically significant associations were found with splenomegaly (P <0.0001), anaemia (P <0.0001), white blood cell count (P = 0.049), hepatomegaly (P = 0.004) and bone pain (P = 0.035). Exponential platelet decay in relation to splenomegaly suggests that platelets increase only when spleen volume decreases substantially
Original languageEnglish
Pages (from-to)528-538
JournalBritish Journal of Haematology
Issue number4
Publication statusPublished - 2012

Cite this